Looking at the filing, I need to extract the key financial data. The filing text provided is primarily the cover page, table of contents, and cautionary language - I need to work with what's substantively disclosed. Let me check: the filing does contain substantive disclosure about the company's quarterly report period, share count, product (YUTREPIA), pipeline (L606), litigation (United Therapeutics), and commercialization activities. This exceeds 150 words of substantive content. The exchange/ticker from the cover page: "LQDA" on "The Nasdaq Stock Market LLC" = NASDAQ:LQDA.

Liquidia Corporation (NASDAQ:LQDA) filed its Form 10-Q for the fiscal quarter ended June 30, 2026, with the U.S. Securities and Exchange Commission, reporting on its commercial operations, pipeline, and ongoing litigation as of that date.

Key Highlights

  • Share count: As of July 29, 2026, there were 89,508,891 shares of common stock outstanding.
  • Commercial product: YUTREPIA is disclosed as the company's commercialized product, with market acceptance and third-party payor coverage cited among forward-looking considerations.
  • Pipeline candidate: L606 is identified as a product candidate for which the company is pursuing potential final FDA approval and commercialization.
  • Ongoing litigation: The filing discloses patent litigation with United Therapeutics filed in the U.S. District Court for the District of Delaware and the U.S. District Court for the Middle District of North Carolina, as well as litigation filed in the Superior Court for Durham County, North Carolina.
  • Collaboration activity: The company discloses commercializing Sandoz's fully substitutable generic treprostinil injection in collaboration with Sandoz, utilizing ICU Medical's CADD-MS 3 ambulatory infusion pump and other devices.
  • Filer classification: Liquidia is classified as a non-accelerated filer and is not a smaller reporting company or emerging growth company.

Liquidia's Q2 2026 Filing: Products, Pipeline, and Litigation Disclosures

Liquidia Corporation, headquartered at 419 Davis Drive, Suite 100, Morrisville, North Carolina 27560, filed its quarterly report for the period ended June 30, 2026. According to the filing, the company had 89,508,891 shares of common stock outstanding as of July 29, 2026. The registrant is incorporated in Delaware and trades under the symbol LQDA on The Nasdaq Stock Market LLC.

The filing identifies YUTREPIA as the company's primary commercialized product, with disclosures addressing regulatory approvals, market acceptance, manufacturing, and third-party payor coverage. The company also identifies L606 as a product candidate, noting considerations around potential final FDA approval, commercialization timing, and the impact of regulatory review and exclusivity developments for competitors. According to the filing, the company is also commercializing Sandoz's fully substitutable generic treprostinil injection, utilizing infusion pumps including ICU Medical's CADD-MS 3, CADD Legacy, and CADD-Solis models, as well as a subcutaneous administration cartridge developed in collaboration with Chengdu Shifeng Medical Technologies LTD.

The filing discloses active patent litigation with United Therapeutics in multiple venues: the U.S. District Court for the District of Delaware, the U.S. District Court for the Middle District of North Carolina, and the Superior Court for Durham County, North Carolina. The company notes that the timeline and outcome of this litigation, including any rehearings or appeals, remain among the forward-looking considerations subject to its cautionary language. The filing's forward-looking statements are the company's own and are subject to the cautionary provisions described therein.

What Was Disclosed

Liquidia Corporation disclosed its unaudited condensed consolidated financial statements and operational update for the quarter ended June 30, 2026, covering its YUTREPIA commercial product, the L606 pipeline candidate, collaboration arrangements with Sandoz, and ongoing multi-venue litigation with United Therapeutics.